A doxycycline-inducible CYP3A4-Caco-2 cell line as a model for evaluating safety of aflatoxin B1 in the human intestine.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
01 Nov 2022
Historique:
received: 03 06 2022
revised: 05 09 2022
accepted: 09 09 2022
pubmed: 14 9 2022
medline: 14 10 2022
entrez: 13 9 2022
Statut: ppublish

Résumé

Exposure of humans to aflatoxin B1 (AFB1) via ingestion of contaminated agricultural products is a major concern for human health throughout the world because epoxidized AFB1, biotransformed from AFB1 by hepatic CYP3A4, is strongly hepatotoxic and hepatocarcinogenic. Intestinal epithelial cells serve as a physical and physiological barrier against xenobiotics via their intercellular tight junction (TJ) seals and the metabolizing enzyme CYP3A4. However, the effect of AFB1 on the intestinal barrier remains unclear. Here, we investigated the influence of AFB1 on these physical and physiological intestinal barriers by means of an in vitro human intestinal model utilizing doxycycline-inducible CYP3A4-expressing Caco-2 cells, in which CYP3A4 activity is comparable to that in the adult human intestine. Cellular toxicity of AFB1 in induced Caco-2 cells (i.e., cells in which expression of CYP3A4 is induced by doxycycline) was approximately 5 times that of uninduced Caco-2 cells. Exposure to 16 µM AFB1 did not decrease the transepithelial electric resistance (TEER; a measure of TJ barrier integrity) in monolayers of uninduced Caco-2 cells to 95.8 % of that in vehicle-treated cells; in contrast, in induced Caco-2 cells, TEER was reduced to 28.8 %. Exposure to 16 µM AFB1 increased paracellular permeation of 4- and 20-kDa dextrans (paracellular permeation markers) through monolayers of induced Caco-2 cells to 5.4 and 5.2 times that through uninduced Caco-2 cells. These results together show that ingested AFB1 can modulate the intestinal barrier, and that inducible CYP3A4-expressing Caco-2 cells are a promising tool for evaluating the safety of food contaminants in the human intestine.

Identifiants

pubmed: 36100150
pii: S0378-4274(22)01734-9
doi: 10.1016/j.toxlet.2022.09.005
pii:
doi:

Substances chimiques

Dextrans 0
Aflatoxin B1 9N2N2Y55MH
Cytochrome P-450 CYP3A EC 1.14.14.1
CYP3A4 protein, human EC 1.14.14.55
Doxycycline N12000U13O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lin Bai (L)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Keisuke Tachibana (K)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Michika Murata (M)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Tetsunori Inoue (T)

Faculty of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Hiroyuki Mizuguchi (H)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Shinichiro Maeda (S)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; Department of Pharmacy, Osaka University Hospital, Suita, Osaka, Japan.

Kenji Ikemura (K)

Department of Pharmacy, Osaka University Hospital, Suita, Osaka, Japan.

Masahiro Okuda (M)

Department of Pharmacy, Osaka University Hospital, Suita, Osaka, Japan.

Tetsuya Kusakabe (T)

Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

Masuo Kondoh (M)

Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan. Electronic address: masuo@phs.osaka-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH